Today, Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) has signed a Protocol of Intentions with the Regional Government of Castilla-La Mancha through the Regional Ministry of Finance, Public Administrations and Digital Transformation to explore opportunities for collaboration on innovation and technological development initiatives in the healthcare field. Within this framework, ROVI joins the Regional Digital Innovation Centre (CRID), strengthening its collaboration with the regional innovation ecosystem and the promotion of technological healthcare initiatives.

The Protocol establishes collaboration aimed at identifying joint lines of action that can contribute to the modernisation of services and the gradual adoption of advanced solutions, considering the strategic priorities of the Castilla-La Mancha Health Service (SESCAM) and the technological capabilities of the ROVI Group through its subsidiary Cells IA Technologies, a pioneer in transforming pathological anatomy through artificial intelligence.

Planned areas of collaboration

Under the Protocol, subject to any specific agreements that may be drawn up, ROVI and the Regional Government of Castilla-La Mancha can assess and develop initiatives aimed at promoting the modernisation of the SESCAM’s services, providing advanced technological solutions and strengthening the region’s healthcare and technology ecosystem.

Pedro Carretero, Director of ROVI’s Hospital and Institutional Relations Area, said: “Healthcare innovation advances more swiftly and has a greater impact when it is built on public-private collaboration. This Protocol with the Regional Government of Castilla-La Mancha establishes a framework for identifying technological initiatives with potential for real application within the healthcare system, always based on rigour, joint assessment and the pursuit of value for professionals and patients, whilst helping to strengthen the region’s innovation ecosystem and employment.”

Likewise, Ignacio Jiménez-Carlés, Director of Operations and Business Development of Cells IA, added: “At Cells IA we work to apply artificial intelligence to clinical processes in a responsible and measurable manner, especially in the pathological anatomy field. This Protocol opens to door to collaboration with the SESCAM on the joint validation and evaluation of tools that can be integrated into clinical practice with the appropriate safeguards, providing support to professionals and contributing to a continuous improvement in the workflows.”

About Cells IA

Cells IA is a technology company within the ROVI Group specialising in the development of digital health and artificial intelligence solutions applied to clinical diagnostics. The company develops medical software platforms and advanced algorithms for the analysis of digital images, especially focused on pathological anatomy and precision diagnostics, helping to improve the efficiency of clinical processes and the diagnostic capabilities of healthcare professionals.

With an international presence and a clear commitment to innovation, Cells IA works in collaboration with hospitals, clinical professionals and research centres to promote the adoption of advanced technologies in clinical practice, favouring more efficient and sustainable healthcare.

About ROVI

ROVI is an international pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Austria and maintains a diversified marketing portfolio of more than 40 products, among which its flagship product, bemiparin, also present in more than 60 countries all over the world, should be highlighted. Likewise, ROVI markets its enoxaparin biosimilar, developed in-house, in Europe and it is also present in approximately 60 countries. ROVI continues to drive the development of the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release that has led, among other developments, to Risperidone ISM® for the treatment of schizophrenia in adults. For further information, please visit www.rovi.es.